Compare GSK plc (GSK) vs Marathon Petroleum Corp (MPC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Marathon Petroleum Corp — how do they compare? GSK plc trades at $50.31 (market cap $102.60B), while Marathon Petroleum Corp trades at $342.56 (market cap $94.48B). The key difference: GSK plc and Marathon Petroleum Corp are close in size by market cap, and GSK plc pays the higher dividend (3.57%). Which is the better fit depends on your goals.
| GSK | MPC | |
|---|---|---|
Market Cap | $102.60B | $94.48B |
Sector | Health | Energy |
52-Week High | $61.18 | $336.42 |
52-Week Low | $38.22 | $159.11 |
Enterprise Value | $123.04B | $121.00B |
Dividend Yield | 3.57% | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.30, down 3.57% today, with a bearish technical signal from moving averages. The company reported strong Q2 2026 earnings of $1.36 per share, beating estimates of $1.27, and announced a $2.52 billion cost-saving plan through 2029. Revenue growth remains steady at 5% constant currency, supported by vaccines and specialty medicines. Analyst consensus shows 31% buy ratings with 55% hold, indicating cautious optimism.
GSK's solid profitability and strategic cost initiatives support long-term growth, but near-term stock performance faces headwinds from bearish technicals and mixed analyst sentiment. Key risks include pipeline execution and regulatory challenges, while institutional ownership trends and recent FDA approvals provide stability. The current valuation at 16.02 P/E offers reasonable entry for patient investors.
Marathon Petroleum (MPC) trades at $342.47, up 6.91% with strong technical momentum and bullish analyst sentiment. The stock demonstrates robust fundamentals with Q2 2026 EPS of $17.73 beating estimates by 22.1%, supported by refining margin strength and disciplined operations. Valuation metrics remain attractive with P/E of 11.67 and EV/EBITDA of 6.87, while maintaining strong profitability with 47.9% ROE.
MPC presents a compelling investment case with projected revenue growth to $153.6B in 2026 and net profit margin expansion to 5.56%. Key risks include refining margin volatility and geopolitical impacts on energy markets. With 25 buy ratings and no sell recommendations, Wall Street consensus targets $332.70, though current price exceeds this level by 2.9%.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Marathon Petroleum Corp
Marathon Petroleum is an independent refiner with 13 refineries in the midcontinent, West Coast, and Gulf Coast of the United States with total throughput capacity of 2.9 million barrels per day. Its Dickinson, ND, facility produces 184 million gallons a year of renewable diesel. Its Martinez, CA, facility will have the ability to produce 730 million gallons a year of renewable diesel once converted. The firm also owns and operates midstream assets primarily through its listed MLP, MPLX.
Read more on MPC →
